Financial Survey: BioLargo (BLGO) vs. Its Peers
by Tristan Rich · The Markets DailyBioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it compare to its competitors? We will compare BioLargo to related businesses based on the strength of its analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Insider and Institutional Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings for BioLargo and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLargo | 0 | 0 | 0 | 0 | N/A |
| BioLargo Competitors | 139 | 1276 | 1591 | 46 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 6.35%. Given BioLargo’s competitors higher probable upside, analysts clearly believe BioLargo has less favorable growth aspects than its competitors.
Volatility & Risk
BioLargo has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.78, meaning that their average stock price is 78% more volatile than the S&P 500.
Profitability
This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLargo | -16.53% | -58.35% | -32.12% |
| BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Earnings & Valuation
This table compares BioLargo and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioLargo | $12.23 million | -$3.50 million | -7.89 |
| BioLargo Competitors | $6.63 billion | $206.77 million | 66.08 |
BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
BioLargo competitors beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.